Financials data is unavailable for this security.
View more
Year on year AstraZeneca PLC grew revenues 3.29% from 44.35bn to 45.81bn while net income improved 81.11% from 3.29bn to 5.96bn.
| Gross margin | 82.17% |
|---|---|
| Net profit margin | 13.31% |
| Operating margin | 18.40% |
| Return on assets | 6.37% |
|---|---|
| Return on equity | 17.29% |
| Return on investment | 8.73% |
More ▼
Cash flow in USDView more
In 2021, cash reserves at AstraZeneca PLC fell by 1.51bn. However, the company earned 5.96bn from its operations for a Cash Flow Margin of 15.94%. In addition the company generated 3.65bn cash from financing while 11.06bn was spent on investing.
| Cash flow per share | 5.85 |
|---|---|
| Price/Cash flow per share | 20.83 |
| Book value per share | 19.24 |
|---|---|
| Tangible book value per share | -10.98 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 80.88% while dividends per share growth only marginally increased 0.21%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 2.48% |
|---|---|
| Div growth rate (5 year) | 1.10% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 17.52 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 34.45 |
More ▼
